Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial-Reference-Cited by-同舟云学术

Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial

Published:2018-11-02 Issue:5 Volume:123 Page:854-860
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Pinsky Paul F.¹^ORCID,Miller Eric¹^ORCID,Prorok Philip¹,Grubb Robert²,Crawford E. David³,Andriole Gerald⁴

Affiliation:

1. Division of Cancer Prevention; National Cancer Institute; NIH; Bethesda MD USA

2. Medical University of South Carolina; Charleston SC USA

3. University of Colorado Health Sciences; Denver CO USA

4. Washington University School of Medicine; St. Louis MO USA

Funder

Centers for Disease Control and Prevention

National Programme for Central Registries, local states

National Cancer Institute

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.14580/fullpdf

Reference11 articles.

1. Mortality results from a randomized prostate cancer screening trial;Andriole;New Engl J Med,2009

2. Screening and prostate cancer mortality in a randomized European study;Schroder;New Engl J Med,2010

3. Prostate cancer screening in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up;Andriole;J Natl Cancer Inst,2012

4. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up;Schroder;Lancet,2014

5. Extended mortality results for prostate cancer screening in the PLCO trial with median 15 years follow-up;Pinsky;Cancer,2017

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer Screening: Theory and Applications;International Encyclopedia of Public Health;2025

2. Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer;Annals of Internal Medicine;2024-07

3. The Role of Baseline Prostate-specific Antigen Value Prior to Age 60 in Predicting Lethal Prostate Cancer: Analysis of a Contemporary North American Cohort;European Urology Oncology;2024-07

4. Overall and non‐lung cancer incidence and mortality in the National Lung Screening Trial: Opportunities for multi‐cancer early detection;Cancer Medicine;2024-06

5. Randomized trials of PSA screening;Urologic Oncology: Seminars and Original Investigations;2024-06